Business Context and Reporting Period
This Form 8-K is filed by Catalyst Biosciences, Inc. (trading symbol: CBIO) for the reporting period of December 2, 2020. The filing addresses a significant regulatory milestone for the Company's lead product candidate.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event rather than financial performance data.
Material Changes
- Regulatory Milestone: On December 2, 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to Marzeptacog alfa (activated), also known as MarzAA.
- Product Indication: MarzAA is a next-generation engineered coagulation Factor VIIa (FVIIa) administered subcutaneously (SQ).
- Target Population: The designation is for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors.
Outlook, Risks, and Management Commentary
Management highlighted the Fast Track Designation as a key development event. The filing incorporates a press release (Exhibit 99.1) detailing this achievement. No specific financial guidance, risk factors, or contingencies are disclosed within the text of this specific 8-K filing.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for detailed clinical context.
- Review the Company's most recent 10-K or 10-Q filings for current financial position, cash runway, and burn rate, as this 8-K contains no financial data.
- Monitor future FDA communications regarding the Fast Track status and potential approval timelines for MarzAA.